Table 3.
Comparison of efficacy between KRAS-mutant patients and KRAS-wild patients.
| Comparison of efficacy in the total 159 patients. | |||
| KRAS-mutant patients (n= 26) | KRAS-wild patients (n= 133) | P value | |
| CR | 0 | 0 | |
| PR | 3 | 58 | |
| SD | 10 | 54 | |
| PD | 13 | 21 | |
| ORR | 3 (11.5%) | 58 (43.6%) | 0.002 |
| DCR | 13 (50.0%) | 112 (84.2%) | <0.001 |
| Comparison of efficacy in the 93 patients receiving first-line chemotherapy. | |||
| KRAS-mutant patients (n= 26) | KRAS-wild patients (n= 67) | P value | |
| CR | 0 | 0 | |
| PR | 3 | 20 | |
| SD | 10 | 35 | |
| PD | 13 | 12 | |
| ORR | 3 (11.5%) | 20 (29.9%) | 0.106 |
| DCR | 13 (50.0%) | 55 (82.1%) | 0.003 |